Pfizer: The Market Is Wrong

Alexandros Michailidis Investment thesis My previous bullish thesis about Pfizer Inc. (NYSE:PFE) from October 2023 did not age well, as the stock delivered a -10% total return over the last half-year, substantially lagging behind the broader market. Despite it, today I want to reiterate my bullish thesis because recent developments suggest that the business continues moving in line with its innovative approach and commitment to create value for shareholders. The market seems to be wrong by overreacting to 2 ...